Guggenheim analyst Michael Schmidt downgrades Arvinas (NASDAQ:ARVN) from Buy to Neutral.
Needham Maintains Buy on Intra-Cellular Therapies, Raises Price Target to $67
Needham analyst Ami Fadia maintains Intra-Cellular Therapies (NASDAQ:ITCI) with a Buy and raises the price target from $65 to $67.